Advanced in Benign Chronic Pemphigus

Henri Montaudie

CHU De Clermont Ferrand
Clermont-ferrand, FR 
Clinical Trials:Currently Recruiting for 3 Trials
Advanced in Benign Chronic Pemphigus
CHU De Clermont Ferrand
Clermont-ferrand, FR 
OverviewLocationsClinical Research

Overview

Henri Montaudie practices in Clermont-ferrand, France. Montaudie is rated as an Advanced expert by MediFind in the treatment of Benign Chronic Pemphigus. Their top areas of expertise are Melanoma, Vitiligo, Hypomelanotic Disorder, and Melasma.

Their clinical research consists of co-authoring 119 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Benign Chronic Pemphigus.

Locations

CHU de Clermont Ferrand
Clermont-ferrand, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Constitution of a National Cohort of Patients With Metastatic Melanoma Resectable Stage II or Stage III or IV or Unresectable Primary With the Objective of Setting up Epidemiological Monitoring and Clinico-biological Database, MELBASE
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Other
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 24, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Biological, Drug
Study Drugs: Cemiplimab, RP1
Study Phase: Phase 2
Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma (Vitilimel Study)
Search for New Predictive Markers of the Immune Response in Vitiligo and Melanoma (Vitilimel Study)
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Other
Study Phase: Not Applicable
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL
Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: Picato Gel
Study Phase: Phase 2
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Radiation, Biological
Study Drug: Nivolumab
Study Phase: Phase 2
View 5 Less Clinical Trials

119 Total Publications

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Montaudie's expertise for a condition
ConditionClose
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile